Egalet (EGLT) Misses Q1 EPS by 16c

Egalet (NASDAQ: EGLT) reported Q1 EPS of ($1.02), $0.16 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $6.92 million.

"The first quarter of 2017 began with the approval of ARYMO ER, the first product developed using our proprietary Guardian Technology, and ended with the deployment of the sales force to educate target health care providers on the risks and benefits of ARYMO ER," said Bob Radie, president and chief executive officer of Egalet. "During the first quarter we saw growth continue with both SPRIX and OXAYDO and we believe our new sales force structure that was deployed at the end of the quarter should maximize the potential opportunity for all three of our products."

As of March 31, 2017, Egalet had cash and marketable securities totaling $105.3 million.

For earnings history and earnings-related data on Egalet (EGLT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c